About: Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.52 (-0.56%)
GALT NASDAQ Galectin Therapeutics Inc
Galectin Therapeutics Inc share price
Atividade de preço de GALT
Último preço
$ 3,520
Variação (24h)
-0,02 USD (0,57%)
Volume
263.85K
Volume (média 4 sem.)
-
Abertura
$ 3,61
Variação do dia
$ 3,45 - $ 3,70
Fechamento anterior
$ 3,54
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
GALT price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals